These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 15276219)

  • 1. Have Halpern et al. (2004) detected 'residual neuropsychological effects' of MDMA? Not likely.
    Lyvers M; Hasking P
    Drug Alcohol Depend; 2004 Aug; 75(2):149-52; discussion 153. PubMed ID: 15276219
    [No Abstract]   [Full Text] [Related]  

  • 2. Residual neuropsychological effects of illicit 3,4-methylenedioxymethamphetamine (MDMA) in individuals with minimal exposure to other drugs.
    Halpern JH; Pope HG; Sherwood AR; Barry S; Hudson JI; Yurgelun-Todd D
    Drug Alcohol Depend; 2004 Aug; 75(2):135-47. PubMed ID: 15276218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive function and mood in MDMA/THC users, THC users and non-drug using controls.
    Lamers CT; Bechara A; Rizzo M; Ramaekers JG
    J Psychopharmacol; 2006 Mar; 20(2):302-11. PubMed ID: 16510488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview.
    Gouzoulis-Mayfrank E; Daumann J
    J Psychopharmacol; 2006 Mar; 20(2):188-93. PubMed ID: 16510477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.
    Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A
    J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The neuropsychology of ecstasy (MDMA) use: a quantitative review.
    Zakzanis KK; Campbell Z; Jovanovski D
    Hum Psychopharmacol; 2007 Oct; 22(7):427-35. PubMed ID: 17896346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress.
    Parrott AC
    J Psychopharmacol; 2006 Mar; 20(2):147-63. PubMed ID: 16510474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Residual neurocognitive features of ecstasy use: a re-interpretation of Halpern et al. (2011) consistent with serotonergic neurotoxicity.
    Parrott AC
    Addiction; 2011 Jul; 106(7):1365-8; author reply 1370-2. PubMed ID: 21635601
    [No Abstract]   [Full Text] [Related]  

  • 9. MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes.
    Reay JL; Hamilton C; Kennedy DO; Scholey AB
    J Psychopharmacol; 2006 May; 20(3):385-8. PubMed ID: 16574712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comment on Halpern et al. (2011).
    Fisk JE; Murphy PN; Montgomery C; Wareing M
    Addiction; 2011 Jul; 106(7):1368-9; author reply 1370-2. PubMed ID: 21635597
    [No Abstract]   [Full Text] [Related]  

  • 11. International Conference on Memory (ICOM-4), University of New South Wales, Sydney, Australia, 16-21 July 2006 Ecstasy/MDMA and Memory Symposium.
    Parrott AC; McGregor IS; Lee TM; Scholey AB; Morgan MJ
    J Psychopharmacol; 2007 Nov; 21(8):895-7. PubMed ID: 17881430
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-term effects of MDMA (Ecstasy) on the human central nervous system revealed by visual evoked potentials.
    Casco C; Forcella M; Beretta G; Grieco A; Campana G
    Addict Biol; 2005 Jun; 10(2):187-95. PubMed ID: 16191672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dark side of ecstasy: neuropsychiatric symptoms after exposure to 3,4-methylenedioxymethamphetamine.
    Karlsen SN; Spigset O; Slørdal L
    Basic Clin Pharmacol Toxicol; 2008 Jan; 102(1):15-24. PubMed ID: 18047478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mental disorders in current and former heavy ecstasy (MDMA) users.
    Thomasius R; Petersen KU; Zapletalova P; Wartberg L; Zeichner D; Schmoldt A
    Addiction; 2005 Sep; 100(9):1310-9. PubMed ID: 16128720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do patients with psychogenic nonepileptic seizures produce trustworthy findings on neuropsychological tests?
    Dodrill CB
    Epilepsia; 2008 Apr; 49(4):691-5. PubMed ID: 18070092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers.
    Dumont GJ; Verkes RJ
    J Psychopharmacol; 2006 Mar; 20(2):176-87. PubMed ID: 16510476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of MDMA, cocaine, and cannabis use severity on distinctive components of the executive functions in polysubstance users: a multiple regression analysis.
    Verdejo-García AJ; López-Torrecillas F; Aguilar de Arcos F; Pérez-García M
    Addict Behav; 2005 Jan; 30(1):89-101. PubMed ID: 15561451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recreational ecstasy use and the neurotoxic potential of MDMA: current status of the controversy and methodological issues.
    Lyvers M
    Drug Alcohol Rev; 2006 May; 25(3):269-76. PubMed ID: 16753651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage?
    Gouzoulis-Mayfrank E; Daumann J
    Addiction; 2006 Mar; 101(3):348-61. PubMed ID: 16499508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ecstasy (MDMA) exposure and neuropsychological functioning: a polydrug perspective.
    Medina KL; Shear PK; Corcoran K
    J Int Neuropsychol Soc; 2005 Oct; 11(6):753-65. PubMed ID: 16248911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.